Discontinuation of synthetic cannabinoids (which are generally full CB1 agonists) (6) leads to a similar withdrawal syndrome (3); conversely, CB1 agonists alleviate CWS symptoms (3, 7). Here, CNR1 is linked to substance withdrawal syndrome.